Back to News
Market Impact: 0.25
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Source: reuters.com
IPOs & SPACsHealthcare & Biotech
Drug developers Retension Pharmaceuticals and TRex Bio filed for U.S. IPOs on Friday, adding to the biotech sector's fall issuance pipeline. The filings signal continued receptivity for biotech listings, though no offering sizes, valuations, or pricing timelines were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Anthropic releases amended IPO prospectus with third-quarter financials
- Oracle Kicks Off $20 Billion Capital Raise
- Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70
- Anthropic Revenue Nears $17 Billion as IPO Nears: Evening Briefing Americas
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Anthropic to Spend $895 Billion in the Years Ahead